Post liver transplant complications of Budd-Chiari syndrome.
Anticoagulants
Deceased organ donor
End-stage liver disease
Hepatic venous thrombosis
Iran
Liver cirrhosis
Liver failure
Liver transplantation
Myeloproliferative neoplasms
Journal
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
ISSN: 0975-0711
Titre abrégé: Indian J Gastroenterol
Pays: India
ID NLM: 8409436
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
18
04
2020
accepted:
14
12
2020
pubmed:
21
3
2021
medline:
18
1
2022
entrez:
20
3
2021
Statut:
ppublish
Résumé
Budd-Chiari syndrome (BCS) is a rare, life-threatening disease characterized by hepatic venous outflow obstruction. Liver transplantation (LT) is widely accepted as an effective therapeutic measure for irreversible liver failure due to BCS. There is debate on differences in the post LT course and complications in patients with BCS as compared to non-Budd-Chiari (NBC) patients. In this retrospective study, data on all patients who received a liver transplant for BCS at the Shiraz Organ Transplantation Center between January 1996 and September 2017 were reviewed and compared to data of a control group who had received liver transplants over the same period but due to other causes (NBC). Out of 4225 patients who received liver transplants in the study period, 108 had BCS and an age- and gender-matched control group consisted of 108 NBC cases. The mean ± standard deviation (SD) of model for end-stage liver disease (MELD) scores were 19.1 ± 3 and 20 ± 3 for BCS and NBC groups, respectively (p = 0.33). One-, 3-, 5-, and 10-year survival rates in the BCS group were as follows: 82%, 78%, 76%, and 76% compared with the NBC rates of 83%, 83%, 83%, and 76%, respectively (p = 0.556). There was no difference between the two groups in complication rates after 6 months. In the later period, vascular thrombosis was more common in BCS. Whole-organ LT from deceased donors in patients with BCS had comparable outcomes with LT due to other causes of end-stage liver disease. In most instances, these patients should receive lifelong anticoagulation.
Sections du résumé
BACKGROUND/PURPOSE
OBJECTIVE
Budd-Chiari syndrome (BCS) is a rare, life-threatening disease characterized by hepatic venous outflow obstruction. Liver transplantation (LT) is widely accepted as an effective therapeutic measure for irreversible liver failure due to BCS. There is debate on differences in the post LT course and complications in patients with BCS as compared to non-Budd-Chiari (NBC) patients.
METHOD
METHODS
In this retrospective study, data on all patients who received a liver transplant for BCS at the Shiraz Organ Transplantation Center between January 1996 and September 2017 were reviewed and compared to data of a control group who had received liver transplants over the same period but due to other causes (NBC).
RESULTS
RESULTS
Out of 4225 patients who received liver transplants in the study period, 108 had BCS and an age- and gender-matched control group consisted of 108 NBC cases. The mean ± standard deviation (SD) of model for end-stage liver disease (MELD) scores were 19.1 ± 3 and 20 ± 3 for BCS and NBC groups, respectively (p = 0.33). One-, 3-, 5-, and 10-year survival rates in the BCS group were as follows: 82%, 78%, 76%, and 76% compared with the NBC rates of 83%, 83%, 83%, and 76%, respectively (p = 0.556). There was no difference between the two groups in complication rates after 6 months. In the later period, vascular thrombosis was more common in BCS.
CONCLUSIONS
CONCLUSIONS
Whole-organ LT from deceased donors in patients with BCS had comparable outcomes with LT due to other causes of end-stage liver disease. In most instances, these patients should receive lifelong anticoagulation.
Identifiants
pubmed: 33743161
doi: 10.1007/s12664-020-01139-3
pii: 10.1007/s12664-020-01139-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
281-286Références
Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med. 2004;350:578–85.
doi: 10.1056/NEJMra020282
Malkowski P, Michalowicz B, Pawlak J, et al. Liver transplantation in patients with Budd-Chiari syndrome. Transplant Proc. 2002;34:629–30.
Ludwig J, Hashimoto E, McGill DB, van Heerden JA. Classification of hepatic venous outflow obstruction: ambiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc. 1990;65:51–5.
doi: 10.1016/S0025-6196(12)62109-0
Plessier A, Valla D-C. Budd-Chiari syndrome. Semin Liver Dis. 2008;28:259–69.
doi: 10.1055/s-0028-1085094
Ferral H, Behrens G, Lopera J. Budd-Chiari syndrome. AJR Am J Roentgenol. 2012;199:737–45.
doi: 10.2214/AJR.12.9098
Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine. 1994;73:21–36.
doi: 10.1097/00005792-199401000-00003
Murad SD, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151:167–75.
doi: 10.7326/0003-4819-151-3-200908040-00004
Klein AS, Molmenti EP. Surgical treatment of Budd-Chiari syndrome. Liver Transpl. 2003;9:891–6.
doi: 10.1053/jlts.2003.50156
Seijo S, Plessier A, Hoekstra J, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–8.
Ringe B, Lang H, Oldhafer K-J, et al. Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology. 1995;21:1337–44.
Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd–Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol. 2006;44:520–8.
doi: 10.1016/j.jhep.2005.12.002
Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl. 2007;13:1285–94.
Malek-Hosseini SA, Habibzadeh F, Nikeghbalian S. Shiraz organ transplant center: the largest liver transplant center in the world. Transplantation. 2019;103:1523–5.
doi: 10.1097/TP.0000000000002581
Raza SM, Zainab S, Shamsaeefar AR, Nikeghbalian S, Malek Hosseini SA. Experience of liver transplant in patients diagnosed with Budd-Chiari syndrome. Exp Clin Transplant. 2018;16:177–81.
pubmed: 28176618
Malek Hosseini SA, Nikeghbalian S, Salahi H, et al. Evolution of liver transplantation program in Shiraz, Iran. Hepat Mon. 2017;17:e60745.